These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20599393)

  • 1. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Singh V; Mohan A; Bharti AC; Das BC
    Cytokine; 2010 Sep; 51(3):245-8. PubMed ID: 20599393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of plasma tumour necrosis factor-alpha and transforming growth factor-beta1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma.
    Kumar S; Guleria R; Mohan A; Singh V; Ali A; Bharti AC; Das BC
    Biomarkers; 2010 Aug; 15(5):446-53. PubMed ID: 20486867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Clin Lung Cancer; 2010 Jan; 11(1):36-44. PubMed ID: 20085866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Eur Respir J; 2010 Oct; 36(4):885-92. PubMed ID: 20185420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients.
    De Vita F; Orditura M; Auriemma A; Infusino S; Catalano G
    J Exp Clin Cancer Res; 1998 Dec; 17(4):413-7. PubMed ID: 10089060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
    Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
    Han JY; Choi BG; Choi JY; Lee SY; Ju SY
    Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
    Buccheri G; Ferrigno D
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
    Holdenrieder S; Stieber P; von Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5981-7. PubMed ID: 15447981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
    Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
    Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.